Cancer Communications (Aug 2024)

SALIRI‐based (raltitrexed plus irinotecan) therapy as a second‐line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non‐interventional, registry study

  • Shuqui Qin,
  • Jin Li,
  • Aiping Zhou,
  • Yanqiao Zhang,
  • Xianglin Yuan,
  • Liangjun Zhu,
  • Baoli Qin,
  • Shan Zeng,
  • Lin Shen,
  • Ying Yuan,
  • Weibo Wang,
  • Jun Liang,
  • Xianwen Zhang,
  • Feng Ye,
  • Ping Chen,
  • Huaizhang Wang,
  • Zhenyan Yu,
  • Lu Yue,
  • Yong Fang,
  • Jianping Xiong,
  • Jianwei Yang,
  • Yiye Wan,
  • Xianli Yin,
  • Wenling Wang,
  • Nong Xu,
  • Xiaohong Wang,
  • Zemin Xiao,
  • Huafang Su,
  • Ying Wang,
  • Kangsheng Gu,
  • Shuiping Tu,
  • Zishu Wang,
  • Bo Liu,
  • Xiaohua Hu,
  • Weixian Liu,
  • Xiaofeng Li

DOI
https://doi.org/10.1002/cac2.12586
Journal volume & issue
Vol. 44, no. 8
pp. 910 – 914

Abstract

Read online

No abstracts available.